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ARTICLE
Drug-tunable multidimensional synthetic gene
control using inducible degron-tagged dCas9
effectors
Dirk A. Kleinjan1, Caroline Wardrope1, Si Nga Sou1 & Susan J. Rosser1,2
The nuclease-deactivated variant of CRISPR-Cas9 proteins (dCas9) fused to heterologous
transactivation domains can act as a potent guide RNA sequence-directed inducer or
repressor of gene expression in mammalian cells. In such a system the long-term presence of
a stable dCas9 effector can be a draw-back precluding the ability to switch rapidly between
repressed and activated target gene expression states, imposing a static environment on the
synthetic regulatory circuits in the cell. To address this issue we have generated a toolkit of
conditionally degradable or stabilisable orthologous dCas9 or Cpf1 effector proteins, thus
opening options for multidimensional control of functional activities through combinations of
orthogonal, drug-tunable artiﬁcial transcription factors.
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Recent advances in our ability to engineer artiﬁcial tran-scription factors have brought the capability to designnovel synthetic gene expression programs within reach. In
particular the clustered, regularly interspaced, short palindromic
repeats (CRISPR)-associated protein Cas9 has proved a powerful
scaffold for the creation of a suite of transcription factors with
desired functionalities1, 2. Cas9 is an RNA-guided DNA binding
protein that can be directed efﬁciently to any genomic sequence
through the use of short single-guide RNAs (sgRNAs), where it
makes double-strand DNA breaks via its two endonuclease
domains3. Inactivating missense mutations in both domains have
created a nuclease-dead Cas9 protein (dCas9) that can be given
new activities by fusion to functional protein domains, commonly
at its C-terminus. For instance, fusion with the transcriptional
activation domain VP64 turns dCas9 into a potent transcriptional
activator, while attachment of the KRAB or SID4x domains
produces a transcriptional repressor4–6. Without further mod-
iﬁcation the dCas9 protein can interfere with the process of
transcription, when targeted to the transcriptional start site of
genes in a process called CRISPRi4, 7. Unfused dCas9 is also used
in the second generation dCas9 transcription system, the SAM
system8, where instead the single-guide RNA (sgRNA) bears an
RNA aptamer that recruits its cognate aptamer-binding protein
fused to the desired functional domain.
A big advantage of the Crispr-Cas9 system is that a single
dCas9 entity can be used to carry out its function at many dif-
ferent sites in the genome simultaneously, by supplying it with
multiple small guide RNAs (sgRNAs). In contrast, in alternative
systems such as TALEs and ZFNs the DNA binding speciﬁcity is
encoded in the effector protein itself and targeting of multiple
genomic sites would therefore require the introduction of a spe-
ciﬁc factor for each of them. However, as the dCas9 protein will
readily combine with any supplied guide RNA in a cell, a clear
drawback is that the combined use of different functionalities is
troublesome and switching between different regulatory states, a
highly desired requisite for the proper functioning of regulatory
circuits, is precluded by the persistence of activating or repressing
dCas9.
To address the need for a system that would allow user-
controlled ﬁne-tuning of dCas9 activity with regard to level and
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Fig. 1 Small molecule inducible degradation control of dCas9 using the Auxin inducible degron. a Schematic overview of the AID-dCas9 system. The IAA17
peptide, which confers sensitivity to degradation upon addition of the plant hormone auxin, is fused to the N-terminus of dCas9. The cullin/skp/rbx
components are present in mammalian cells, but auxiliary protein TIR1 has to be externally supplied. Upon addition of auxin a complex is formed with E2
ligase, resulting in poly-ubiquination and proteasomal degradation. IAA17-dCas9 and osTIR1 can be expressed from separate plasmids, allowing
independent tetracyclin-inducible control of osTIR1 expression, or from a single combined construct suitable for Flp-mediated integration into FRT
containing genomic insertion platforms. Effector domains of interest (e.g., VP64) can be fused to the C-terminus of AID-dCas9. b The IAA17 degron tagged
dCas9 fusion protein is sensitive to degradation upon addition of auxin only in the presence of osTIR1. Western blot of HEK293FT cells transfected with the
constructs shown in the table in the presence or absence of added auxin (400 μM) and probed with Cas9 antibody. Histone H3 antibody was used as
loading control c Placing osTIR1 under control of a Tetracyclin (Tet)-inducible promoter results in degradation of IAA17-dCas9 only in the presence of both
auxin and tetracyclin, effectively creating an AND or NAND gate depending on the C-terminal effector domain attached to dCas9. HEK293FT cells were
transfected with pCMV-IAA17-dCas9 and pCMV-2TetO-osTIR1 and tetracycline or auxin were added as indicated in the table. A control GFP expression
plasmid was co-transfected. Samples were probed on Western blot with Cas9 antibody. GFP antibody was used as loading control
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01222-y
2 NATURE COMMUNICATIONS |8:  1191 |DOI: 10.1038/s41467-017-01222-y |www.nature.com/naturecommunications
timing (in addition to its target speciﬁcity bestowed by gRNAs)
we aimed to generate a toolkit of drug-controllable degron tagged
dCas9 variants. A degron is a peptide domain whose presence
confers a greatly increased rate of protein degradation, and a
variety of degrons have been described9. We employed two
oppositely functioning small-molecule inducible degron systems,
the Auxin-Inducible Degron (AID) and the ecDHFR destabilising
domain (ecDDD), and tested their ability to control the stability
of Streptococcus pyogenes dCas9. The AID degron system requires
tagging the protein of interest with a domain (derived from the
Arabidopsis thaliana IAA17 protein) that is sensitive to the plant
hormone auxin10. In the absence of auxin, stability of the IAA17
degron tagged fusion protein is unaffected, but addition of auxin
to the medium promotes interaction with an E3 ubiquitin ligase
SCF complex containing the auxin perceptive F-box protein
TIR1, which recruits an E2 ubiquitin conjugating enzyme leading
to rapid poly ubiquination and degradation by the proteasome
(Fig. 1a). While other parts of the SCF complex are endogenously
present, application of the AID system in mammalian cells
requires co-expression of the auxiliary protein TIR1, in particular
a thermo-stable version from rice plants (osTIR1)10, 11.
The ecDHFR destabilising domain (ecDDD) is an unfolded,
structurally unstable domain derived from the Escherichia coli
dihydrofolate reductase (DHFR) gene, which was evolved for
enhanced instability by introduction of two additional missense
mutations (R12Y/Y110I), which when fused to proteins of
interest similarly targets the fusion protein for rapid proteasomal
degradation12. In contrast to the AID the ecDDD does not
require any additional factors to function in mammalian cells.
The small-molecule drug trimethoprim (TMP) can bind and
stabilise the ecDDD in the fusion protein and prevent its pro-
teosomal degradation in a concentration dependent manner12.
In this study we generate a set of dCas9 family proteins fused
with the AID and ecDDD degrons and characterise their cap-
ability for drug controlled protein destabilisation and functional
tunability. We show that attachment of the AID does not impair
the ability of dCas9-effector fusion proteins to regulate gene
expression using both S. pyogenes and S. aureus dCas9, while
addition of auxin induces their rapid and concentration depen-
dent degradation. The ecDDD is less effective for destabilisation
of dCas9 variants, but can be used to stabilise effector domain
fusions of an aptamer binding protein (the MS2 coat protein)
upon TMP addition, thus enabling multi-dimensional drug-tun-
able gene control via the use of AID-dCas9 in combination with
aptamer containing guide RNAs.
Results
Auxin inducible control of dCas9. We started by cloning the
auxin dependent degron IAA17 at the N-terminus of a catalyti-
cally inactive S. pyogenes Cas9 (SpdCas9 (D10A, H480A)) in a
mammalian expression construct. To allow for easier subsequent
stable insertion into the genome of selected cell types via
recombinase mediated genomic integration we generated a con-
struct incorporating an FRT-site followed by a promoter-less
hygromycinR gene cassette (Fig. 1a). To test whether the fusion
protein is properly expressed and has acquired sensitivity to the
addition of auxin to the medium we transfected HEK293FT cells
and tested for the presence of IAA17dCas9 by western blot
(Fig. 1b). As the AID system requires the auxiliary factor TIR1 we
performed transfections with and without co-transfection of an
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Fig. 2 Auxin controllable functional activity of the AID-dCas9-PR synthetic transcription factor a Dual-luciferase assay on HEK293s transiently transfected
with AID-dCas9-PR, an sgRNA expression construct (gRNA_1), a construct containing ﬁreﬂy luciferase under control of a minimal promoter with 8 binding
sites that are recognised by gRNA_1 (p8*BS-I-minP-Luc) and a Renilla luciferase control plasmid. Auxin was added to the cultures where indicated. b A
stably transfected CHO cell line with AID-dCas9-PR was transfected with guide RNAs targeting the promoter regions of RasL11a and Arpc1b. RNA levels
after 48 h were assessed by rtqPCR. Upregulation was largely abrogated in the presence of auxin. c Upregulation of endogenous genes in HEK293 cells by
auxin-inducible degron-tagged dCas9-PR is similarly affected by the presence of auxin. Expression levels of four genes, ASCL1, IL1RN, OLIG2 AND SOX9,
representing a wide range of potential upregulation were assayed by rt-qPCR. Error bars denote± s.d. (n= 3), (2-tailed t-test, (**) P< 0.01, (*) P< 0.05,
(ns) not signiﬁcant). Black columns, no sgRNA transfected (NT); Blue columns, no auxin added; Red columns, auxin added
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osTIR1 expression construct. Expression of IAA17dCas9 reveals a
stable protein of the expected size, which is unaffected by auxin
addition in the absence of osTIR1. Co-transfection of osTIR1 in
the absence of auxin produces a moderately destabilised
IAA17dCas9 fusion protein, presumably due to the presence of a
tiny amount of auxin in the culture media or a low degree of
interaction between the IAA17 tag and osTIR1 even in the
absence of auxin. Combined addition of auxin and osTIR1 co-
transfection leads to efﬁcient degradation of IAA17dCas9
(Fig. 1b).
AND-gate logic with IAA17dCas9 and osTIR1. The dependence
for effective IAA17dCas9 removal on two separate factors (auxin
and osTIR1 presence) suggested the system could be utilised as an
AND-type logic gate. To test this option we placed the osTIR1
complementary DNA (cDNA) under the control of a tetracyclin
inducible promoter. Cells were co-transfected with IAA17dCas9
and CMV-2TetO-osTIR1 and auxin or tetracyclin were added
individually or in combination (Fig. 1c). Only in the presence of both
drugs is the IAA17dCas9 protein efﬁciently degraded, demonstrating
the feasibility of using the system as an AND or NAND gate
depending on the effector domain fused to IAA17-dCas9.
AID-dCas9 artiﬁcial transcription factors. While the use of two
plasmids to create a (N)AND-gate option can be useful, it is
generally undesirable to require co-transfection of multiple con-
structs; therefore we designed a plasmid construct for simulta-
neous co-expression of IAA17-dCas9 and osTIR1 through linkage
via a p2a peptide bridge (cassette subsequently referred to as
AID-dCas9). A unique XmaI restriction site at the C-terminus of
the dCas9 cDNA moiety allows for the introduction of selected
effector domains. We produced versions with VP64 and PR (p65-
rTa) transactivation domains as well as the SID4x repression
domain6, 13 (Supplementary Fig. 1a, b). Next we tested the ability
of the degron tagged dCas9-PR to induce gene expression of
target genes. We co-transfected the AID-dCas9-PR with a
reporter construct expressing luciferase under control of a
minimal promoter containing eight recognition sites for an arti-
ﬁcial guide RNA (gRNA-1), and observed a strong luciferase
signal in the presence of gRNA-1. No luciferase activity was
detected in the absence of the gRNA-1. Addition of auxin resulted
in a sharp drop in luciferase output (Fig. 2a). To test the capacity
for induction of endogenous genes we co-transfected AID-dCas9-
PR with a mix of guide RNAs targeting the ASCL1 and SOX9
genes. Both genes show clear upregulation of expression, which is
strongly reduced in the presence of auxin (Supplementary Fig. 2a,
b), demonstrating the potential of AID-dCas9-PR as a drug-
controllable transcriptional activator.
We proceeded to produce stable cell lines with the AID-dCas9-
PR construct via Flp mediated integration into transcriptionally
competent genomic landing sites in HEK293Trex-FlpIn and
CHO-K1 derived cell lines. Functional activity of the integrated
AID-dCas9-PR transactivator was conﬁrmed via transfection of
ﬂuorescent or luciferase reporters under control of artiﬁcial
gRNA binding site containing promoters and co-transfection of
the corresponding guide RNAs. Addition of auxin to the medium
severely reduced reporter output, to below detectable level in the
case of the ﬂuorescent reporters (Supplementary Fig. 2c).
Similarly, targeting a number of endogenous genes via transfec-
tion of mixes of expression plasmids for 3 or 4 sgRNAs to sites
within the same promoter region (RasL11a and Arpc1b in CHO
cells (Fig. 2b) and ASCL1, IL1RN, OLIG2 and SOX9 in HEK293
cells (Fig. 2c)) resulted in clear transcriptional upregulation,
which was markedly reduced in the presence of auxin.
Tunability and kinetics of AID-dCas9. Gene expression pro-
grammes of natural genes often involve a tightly regulated spatio-
temporal on- and off-turning, in some cases requiring fast
switching between expression states, in addition to strict dosage
control. We tested the dosage dependence of AID-dCas9-PR by
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Fig. 3 Concentration dependence and kinetics of the AID-dCas9-effector system. a Western blot on protein extracts from AID-dCas9 expressing HEK293
cells probed with Cas9 and histone H3 (control) antibodies showing the degradation efﬁciency of AID-dCas9 is dependent on the auxin concentration in
the media. b Functional tunability of AID-dCas9 effectors. A stable AID-dCas9-PR cell line was transfected with a mix of guide RNAs targeting the ASCL1
promoter region. Auxin was added to the concentrations indicated. mRNA induction levels decreased with increasing auxin concentration. Black columns,
NT, no sgRNA transfected; Blue columns, no auxin added; Red columns, auxin added at indicated concentration. Error bars denote± s.d. (n= 3), (two-tailed
t-test, (**) P< 0.01, (*) P< 0.05, (ns) not signiﬁcant). c Time course of the disappearance of AID-dCas9. Western blot of samples taken at the indicated
time periods after addition of auxin. d Media wash-out and replacement with media without auxin results in detectable reappearance of AID-dCas9 within
30min
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assaying protein stability under increasing auxin concentration,
showing an inverse correlation between auxin concentration in
the medium and residual presence of the protein (Fig. 3a). This
allows tunability of AID-dCas9-effector function as demonstrated
by auxin concentration dependent upregulation of the endogen-
ous ASCL1 (Fig. 3b), IL1RN and OLIG2 genes (Supplementary
Fig. 3a, b). messenger RNA (mRNA) levels of dCas9-PR itself are
unaffected by auxin (Supplementary Fig. 3c). Next we assayed the
kinetics of the AID-dCas9 system by monitoring its dis-
appearance over time after addition of Auxin (Fig. 3c), and its
reappearance following wash-out of the drug (Fig. 3d). Cells were
grown for 24 h to allow build-up of the protein. After addition of
auxin samples were collected at deﬁned intervals. Clearance of the
pool of AID-dCas9-PR protein took 1–2 h, with an estimated
half-life of <15 min, in accordance with reports on other AID
tagged proteins11, 14 (Fig. 3c). Next, cells were grown in the
presence of auxin for 24 h before being replaced with medium
lacking the drug. Detectable levels of the protein reappeared
within 30 min, increasing back to maximum level over the next
3–7 h (Fig. 3d).
Orthogonal, auxin degradable dCas9 variants. Natural gene
networks often rely on fast switching interactions of multiple
transcriptional activators, repressors and other chromatin mod-
ifying factors with cohorts of responsive target promoters. To
enable recreation of such behaviours in artiﬁcial systems, allowing
rapid and diverse, independently controllable functional activity,
we sought to expand our system by developing a set of ortho-
gonal, auxin-degradable synthetic transcription factors. We ﬁrst
replaced the S. pyogenes dCas9 cDNA in our AID vector with a
small multiple cloning site upstream of an HA-tag, into which we
inserted several alternative, orthogonal CRISPR effector proteins
(S. thermophiles 1 dCas9, S. aureus dCas9, A.s Cpf1, L.b Cpf1 and
F.n Cpf1)15, 16. Western blots of HEK293 and CHO-K1 cells
transfected with this set revealed the auxin induced degradation
potential of these orthogonal AID-tagged factors (Supplementary
Fig. 4a, b). Remarkably the AID-Cpf1 factors showed a clear
difference in response to the drug between the cell lines. Although
the reason is presently unclear, this could be due to differences in
the expression levels of some auxiliary factors (e.g., SCF complex
subunits) in combination with reduced accessibility of the IAA17
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representation of the AID-Sa-dCas9-VP64 construct. b Western blot of HEK293-Trex-FlpIn cells stably expressing AID-Sa-dCas9-VP64 and treated with
increasing concentration of auxin as indicated. c Dual luciferase assay on stably expressing AID-Sa-dCas9-VP64 cells transfected with a luciferase reporter
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tag at the N-termini of the Cpf1 proteins. Disappearance of S.
aureus dCas9 in both cell lines upon treatment suggested SadCas9
as a promising orthogonal auxin-controllable transcription factor
(Supplementary Fig. 4a, b). We replaced the HA-tag with a VP64
transactivation domain in the AID-Sa-dCas9 construct and gen-
erated a stably expressing line in HEK293 cells (Fig. 4a). Auxin
dependent protein stability of AID-SadCas9-VP64 in this line was
conﬁrmed by Western blot (Fig. 4b). Using an S. aureus sgRNA
speciﬁc for a repeated site in the promoter of a luciferase reporter
construct we demonstrate functional activity of AID-SadCas9-
VP64, which largely disappears in the presence of auxin (Fig. 4c).
Similarly the induction of an mKate reporter under control of a
multiple S. aureus sgRNA target site-containing minimal pro-
moter by AID-SadCas9-VP64 in the presence of the sgRNA is
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abrogated upon addition of auxin (Fig. 4d). This indicates the
potential of AID-SadCas9-VP64 as a potent orthogonal, drug-
controllable artiﬁcial transcription factor.
dCas9 proteins with the ecDHFR destabilising domain. While
orthogonal AID dCas9 proteins can be tagged with different
effector domains to carry out a diverse range of activities,
increased versatility would be gained by having these functions
under control of independent degron domains regulated by dif-
ferent small-molecule drugs. The ecDHFR DD (ecDDD) is an
inducible degron that functions in opposite direction to the AID
degron, i.e., its intrinsically unstable fusion protein is stabilised by
addition of the drug trimethoprim (TMP) to the medium12
(Supplementary Fig. 5a). We ﬁrst attached the ecDDD to S.
pyogenes dCas9. Though some residual protein was detectable by
Western blot, stability of the fusion protein was greatly improved
by addition of TMP (Supplementary Fig. 5b). Next we con-
structed ecDDD tagged versions of the set of orthogonal dCas9 or
Cpf1 proteins (S. thermophiles 1 dCas9, S. aureus dCas9, As.Cpf1,
Lb.Cpf1 and Fn.Cpf1). With the exception of a moderate effect on
SadCas9, the addition of the ecDDD degron did not appear to
affect the stability of the set of orthogonal Cas9 or Cpf1 proteins
when transfected in HEK293FT cells (Supplementary Fig. 5c). To
investigate whether cell-type speciﬁc characteristics would affect
degradation efﬁciency we next tested the effect of the degron-tag
in CHO-K1 cells. CHO cells are an important resource in the
biotechnology industry and a valuable target for systems that
enable the drug controlled manipulation of gene expression
output17. Interestingly the sensitivity of our panel of degron-
tagged Cas9 or Cpf1 proteins to proteosomal degradation is
markedly enhanced in CHO cells compared with 293 cells,
showing a clear difference in drug dependent stability of the
fusion proteins for most of the constructs in both the AID and
ecDDD degron tagged sets (Supplementary Fig. 5d).
Stereo-tuner dCas9. While the limited instability-conferring
performance of the ecDDD on the set of orthogonal dCas9/Cpf1
proteins might allow some useful modulation of functional out-
put we reasoned that the relatively large size of the dCas9-effector
proteins may affect its sensitivity to the ecDHFR degron. We
therefore shifted our focus to applying the ecDDD degron to the
smaller MS2 core protein (MCP) used as effector-supplying factor
in the CRISPR SAM system8, with the aim to achieve enhanced
tunability of dCas9-effector activity through double degron tag-
ging (Fig. 5a). In the SAM system the guide RNA scaffold is
engineered to contain two MS2 aptamers, which are recognised
by the MCP protein to which various effector domains (e.g., VP64
or p65AD-Hsf1) can be attached. We inserted an MCP-VP64
module into our ecDHFR expression vector to generate a TMP
stabilisable ecDHFR-MCP-VP64 fusion protein. While we ﬁnd a
low level of ecDHFR-MCP-VP64 present even in the absence of
TMP, addition of the drug effects stabilisation in a concentration-
dependent manner (Fig. 5b). We show that attachment of the
ecDHFR degron does not affect the ability of the fusion protein to
induce transcriptional activation in conjunction with AID-dCas9
(Fig. 5c). Using our luciferase assay we show that addition of
TMP and/or auxin to the culture medium can up and down
regulate the expression of luciferase from a responsive promoter
(Fig. 5c). Tagging of a different aptamer binding protein, utilising
the PP7 aptamer, with the ecDDD degron was recently also
shown to be effective for tunable transcriptional activation18.
Here we combine stabilisation of the ecDDD tagged MCP-
effector module with the tunable degradation of the AID-dCas9
protein. We call this system ‘stereo-tuner dCas9’, and envisage
that combination of the domain-less AID-dCas9 DNA binding
module with various ecDHFR-MCP-effector domain plasmids
will allow precisely targetable functional activities that can be
ﬁnely tuned in opposite directions by two independent small
molecule drugs.
Discussion
A major aim in synthetic biology is the development of versatile
and programmable genetic regulators that enable strict control of
gene expression programmes. The ability to regulate the stability
of such synthetic transcription factors through application of
small molecule drugs will enable a more precise control over the
timing and dosage of their activity and enhance the scope of their
application in basic science and therapeutic settings. We
demonstrate here that the auxin inducible degron and to lesser
extent the ecDHFR degron are effective drug-inducible reg-
ulatable domains for S. pyogenes dCas9. The AID degron also
functions with selected orthogonal dCas9 and Cpf1 proteins, in
particular with S. aureus dCas9, while the ecDHFR degron allows
a more subtle modulation of their expression levels, or of the level
of an aptamer binding protein linked with an effector domain.
We envisage that tailored combinations of the orthogonal, degron
tagged effector variants from this toolkit will enable the precise
targeting of a variety of functional domains to their desired
destination in a precise, timing and dosage controlled manner.
Furthermore, the range of inducible dCas9/dCpf1 factors can be
expanded with existing tools such as a recently reported
tamoxifen-inducible dCas919. In that system however, the dCas9-
ER is not degraded but sequestered in the cytoplasm until
application of the drug induces passage into the nucleus, and thus
it does not have the beneﬁt of the increased, controllable turn-
over rate of the AID-dCas9 system that can enable faster
switching between different functional activities. Moreover, the
use of tamoxifen/estradiol as inducer may be less suitable in
certain situations due to the potential for unwanted side effects of
the drug, which is unlikely to be an issue with the plant hormone
auxin. The availability of a range of small molecule-inducible
factors controlled via different modes of action will enable the
Fig. 5 Stereo-tuner dCas9 system. a Schematic overview of the system. An effector-less dCas9 is tagged with the auxin-inducible degron allowing inducible
degradation upon addition of auxin. Two MS2 aptamer sequences are included in the single-guide RNA scaffold, as used in the Crispr/SAM system8. A
transcriptional effector domain (e.g., VP64) is brought in by the MS2 aptamer-interacting MS2 core protein (MCP) which is fused to the ecDHFR
destabilisation domain (ecDDD). Addition of the small molecule drug trimethoprim (TMP) improves the stability of naturally destabilised ecDHFR fusion
proteins. PIC, Polymerase II initiation complex. bWestern blot with HA antibody showing TMP concentration dependent stabilisation of the ecDHFR-MCP-
VP64-5HA protein. β-actin antibody is included as loading control. c Dual-luciferase assay using a ﬁreﬂy luciferase reporter driven from a minimal
promoter with eight copies of a guide RNA target sequence (gRNA-1) in an effector-less AID-dCas9 expressing cell line. A ubiquitous Renilla luciferase
construct was co-transfected as internal control. In the presence of the MS2 aptamer bearing gRNA-1, luciferase activity is produced by transfection of a
dCas9-VP64 plasmid (ﬁrst lane) or by the co-expression of the endogenous AID-dCas9 with the pecDHFR-MCP-VP64 effector module, and can be
enhanced by TMP administration. Addition of auxin to the medium, affecting IAA17-dCas9 stability, abrogates luciferase activation. Grey columns,
controls; Light blue column, no TMP, no auxin; Dark blue columns, TMP added; Red columns, auxin added. Error bars denote± s.d. (n= 3) (two-tailed t-
test, (**) P< 0.01)
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design of tailored combinations of dCas9 effectors for speciﬁc
applications. Another potential advantage of the AID-dCas9
system is its dependence on the presence of both auxin and
osTIR1 expression that can be exploited by placement of the
osTIR1 gene under the control of spatio-temporal or condition-
dependent promoters, thus enabling tissue-speciﬁc abrogation of
dCas9-effector activity. Even though in this study the auxin
inducible degron was attached to nuclease dead Cas9 (dCas9) the
same drug-inducible degradability could be extended to the
nuclease active version of Cas920. In situations were potential off-
target cutting could be an issue21 it may be beneﬁcial to be able to
limit the period during which active Cas9 is present within the
cell.
In conclusion, we believe that the AID-dCas9 system and its
extension with the ecDDD-MCP aptamer binding module
described here with its small molecule-inducible tunability adds a
powerful functionality to the rapidly expanding range of dCas9
effectors in the synthetic biology toolkit.
Methods
Cell culture. HEK293FT cells (Invitrogen R70007) were grown at 37 °C in a 5%
CO2 atmosphere in Dulbecco’s modiﬁed Eagle’s medium (DMEM)(Gibco; Life
Technologies) supplemented with 10% FBS (Gibco; Life Technologies), 4 mM
glutamine and 1% penicillin-streptomycin (Gibco; Life Technologies). CHO-K1
cells were grown in Ham’s F12 medium with 10% FBS (Gibco; Life Technologies),
4 mM glutamine and 1% penicillin-streptomycin (Gibco; Life Technologies) at 37 °
C and 5% CO2. For transient transfections cells were seeded at 0.5×105 cells per
well in 24 well plates and transfected the following day with an appropriate amount
of each plasmid in Opti-MEM reduced serum medium (Life Technologies) using
Lipofectamine 3000 (Invitrogen). sgRNAs were produced in the cell from a U6
promoter construct into which 20 nucleotide guide sequences were cloned
upstream of the appropriate species-speciﬁc sgRNA scaffold. GuideRNA recogni-
tion sequences used in upregulation experiments were chosen from the literature or
designed using the Benchling Crispr design tool (https://benchling.com/crispr) and
are listed in Supplementary Table 1 (Supplementary information). For upregula-
tion of endogenous genes the constructs for 3 or 4 sgRNAs against different sites
within the target gene promoter were combined to make a guideRNA mix for
that gene.
For the experiment involving tetracyclin induction of pCMV-2TetO-osTIR1,
HEK293Trex-FlpIn cells (Invitrogen) were grown in DMEM/Glut/PenStrep with
10% Tet system approved FBS (Clontech 631107).
Stable cell lines expressing the AID-dCas9-effector-osTIR1 cassette were
generated using the 293Trex-FlpIn cell line (Invitrogen) or an in-house CHO cell
line (CHO-B4; CHO-K1 derived) with a randomly integrated SV40 promoter-FRT
site-Neomycin resistance gene containing cassette in its genome. Cells were
transfected with the relevant construct containing an FRT site immediately
upstream of a promoter-less Hygromycin resistance gene and a Flp recombinase
expression plasmid (pCaggs-Flpe). Hygromycin was added 24 h post transfection at
125 μg ml−1 for 293Trex-FlpIn cells or 350 μg ml−1 for CHO-B4 cells.
CHO-K1 cells were obtained commercially (ATCC catalogue number CCL-61).
Blasticidin and zeocin were periodically added to the growth medium of 293Trex-
FlpIn cells to maintain selective pressure. Cells were monitored for mycoplasma
contamination using the LookOut mycoplasma PCR detection kit (Sigma
MP0035).
For functional assays drugs (0.5 mM auxin (Sigma I5148) in ethanol; 5 mM
TMP (Cayman Chemical 16473) in DMSO) or vehicle were added 1 h prior to
transfection and cells were harvested after 48 h. For tunability assays auxin was
used at the lower concentrations indicated in the ﬁgures. For western blots, unless
where indicated otherwise, drugs or vehicle were added 24 h following transfection
and cells were collected at 48 h after transfection. Recoverability from auxin
induced degradation was tested by growing cells in 0.5 mM auxin for 24 h, at which
point the media was replaced with fresh media without auxin. Cells were grown in
this fresh media for the indicated time period before being harvested.
Plasmids. The plasmids used in this study were constructed via direct subcloning
or PCR ampliﬁcation of genes and functional domains from a variety of donor
plasmids obtained from the Addgene plasmid repository, including Addgene
#47106 (gift from Charles Gersbach), #55195 (gift from Timothy Lu), #63798 (gift
from George Church), #64113 (gift from Thoru Pedersen), #62322 (gift from
Wendell Lim and Stanley Qi) and #61594, #61424, #69982, #69976, #69988 (gift
from Feng Zhang). Further plasmids used were pcDNA5TO (Invitrogen), and
pNHK36 and pMK43 (Riken BioResource Center, Japan). Other domains were
synthesised as gBlocks (IDT).
RNA extraction and quantitative RT-PCR. Transfections were carried out in
triplicate. Cells were collected by brief trypsinisation, centrifugation and resus-
pension in RNA lysis buffer. RNA extraction was performed with the EZNA Total
RNA Kit 1 (Omega Biotek) according to the manufacturer’s protocol. In total 2 mg
of total RNA was DNAseI treated, followed by reverse transcription using Super-
Script III (Invitrogen) using random hexamer primers. Triplicate qPCR reactions
for each sample were run in a StepOnePlus real-time PCR machine using Pow-
erSybrGreen qPCR-mix (Life Technologies). Primer sequences used are listed in
Supplementary Table 1 (Supplementary information). Data were analysed by the
ΔΔCt method, normalised to GAPDH or RCN1 expression and reported as the
mean± s.d. of three biological replicates averaged over three technical replicates.
Statistical analysis was done as standard on the biological triplicates using a two-
tailed Student’s t-test
Western blot analysis. Cells grown in the presence or absence of auxin or TMP
were lysed in RIPA buffer (50 mM Tris pH7.5, 150 mM sodium chloride, 0.1%
sodium dodecyl sulphate, 0.5% sodium deoxycholate, 1% Triton-X100) with
complete protease inhibitors (Roche). Lysates were centrifuged and transferred to a
fresh tube. Normalised amounts of protein were loaded onto a 4–15% acrylamide
gradient gel (Bio-Rad Mini Protean TGX) and run in Tris-glycine running buffer
(25 mM Tris, 192 mM glycine, (20% (v/v) methanol (pH 8.3)). Gels were electro
blotted onto PVDF membrane in CAPS transfer buffer (10 mM 3-(cyclohex-
ylamino)-1-propanesulfonic acid, 10% methanol (pH 11.0)). In some cases gels
were blotted overnight on nitrocellulose membrane in Tris-glycine blotting buffer
(25 mM Tris, 192 mM glycine). Membranes were blocked overnight at 4 °C in 5%
milk powder (Marvel) in PBS-T (PBS, 0.1% Tween-20), before being incubated for
at least 4 h with primary antibody against S.pyogenes Cas9 (EpiGentek Cas9
polyclonal A-1111 or Clontech GuideIT Cas9 polyclonal 632607 (1:3000)), anti-
HA (Sigma HA-7; 019K4833 (1:6000)) or S.Aureus Cas9 (Diagenode C15310259
(1:3000)). Anti histone H3 (Abcam Ab1791 (1:10,000)), anti-GFP (Clontech Living
Colors monoclonal JL-8, 632380 (1:6000)) or
HRP-conjugated anti-beta-Actin (Sigma monoclonal BA3R, MA5-15739-HRP
(1:6000)) antibodies were used as loading controls. After washing in PBS-T
membranes were incubated with HRP-conjugated secondary antibodies for> 1 h.
Signal was detected using WesternSure premium chemiluminescence substrate
(LiCor 926–95000) on a LiCor c-Digit instrument. For imaging on the LiCor CLX
blots were incubated with LiCor IRDye secondary antibodies: IRDye 800CW
donkey anti-mouse 926–32,212 (1:10,000), and IRDye 680LT donkey anti-rabbit
926–68023 (1:10,000). Images were captured in Image Studio Lite 3.1.4 (LiCor
biosciences) and processed in Adobe Photoshop. Full images are shown in Sup-
plementary Fig. 6.
Luciferase assays. Cells were transfected with a ﬁreﬂy luciferase reporter con-
struct harbouring multiple guideRNA recognition sites upstream of a minimal
promoter, alongside an appropriate guideRNA expressing construct, a degron-
dCas9-effector construct and a Renilla luciferase internal control plasmid. After 48
h cells were lysed in Passive Lysis buffer and Fireﬂy and Renilla luciferase induced
luminescence levels were measured for each sample using the dual-luciferase kit
(Promega E1910) on a Modulus II microplate reader (Turner Biosystems).
Fluorescence imaging. Fluorescence images were captured on a Leica DM IL LED
microscope with a Leica DFC3000G camera using Leica Application Suite X
software.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its Supplementary information. Addi-
tional data will be available online at the Edinburgh University Datashare repo-
sitory (doi:10.7488/ds/2121).
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